Annikka Weissferdt

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Tina Cascone, Cheuk Hong Leung, Annikka Weissferdt et al. · Nature Medicine · 2023 · 206 citations · Full text

Medicine, Oncology, Pharmacology +17

Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients

Edwin R. Parra, Carmen Behrens, Jaime Rodriguez‐Canales et al. · Clinical Cancer Research · 2016 · 177 citations · Full text

Medicine, Oncology, Pathology +17

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Edwin R. Parra, Pamela Villalobos, Carmen Behrens et al. · Journal for ImmunoTherapy of Cancer · 2018 · 173 citations · Full text

Medicine, Immunology, Oncology +17

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

Tina Cascone, William Nassib William, Annikka Weissferdt et al. · Journal of Clinical Oncology · 2019 · 145 citations

Medicine, Immunology, Oncology +17